https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-02T08:54:56.63Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Community Nurses"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many full-time equivalent district nurses worked in the NHS in England in each financial year since 2009-10.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "tablingMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "tablingMemberPrinted" : [{"_value" : "Dr Dan Poulter"}
], "uin" : "23844"}
, {"_about" : "http://data.parliament.uk/resources/1714076", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714076/answer", "answerText" : {"_value" : "The Department meets regularly with the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including access to medicines. The NICE has recommended Enhertu, also known as trastuzumab deruxtecan and made by Daiichi Sankyo, for use through the Cancer Drugs Fund, for the treatment of HER2-positive metastatic or unresectable breast cancer. It is available to eligible National Health Service patients in England, in line with the NICE\u2019s recommendations.<\/p>
The NICE is currently evaluating Enhertu for the treatment of HER2-low metastatic or unresectable breast cancer. Following negotiations between NHS England and the company, which concluded without a commercial agreement to make it available at a cost-effective price for the NHS, the NICE published final draft guidance on 5 March 2024, that does not recommend it as an option for this indication. The NICE remains open to further discussions with NHS England and the company, and currently expects to publish final guidance on 15 May 2024.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-02T11:47:11.07Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Trastuzumab Deruxtecan"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what representations she has made to NICE on the availability of Enhertu.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4389", "label" : {"_value" : "Biography information for Ruth Cadbury"}
}
, "tablingMemberConstituency" : {"_value" : "Brentford and Isleworth"}
, "tablingMemberPrinted" : [{"_value" : "Ruth Cadbury"}
], "uin" : "23881"}
, {"_about" : "http://data.parliament.uk/resources/1714079", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714079/answer", "answerText" : {"_value" : "
Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.<\/p>
The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T09:02:05.22Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Gabapentin"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23890"}
, {"_about" : "http://data.parliament.uk/resources/1714080", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714080/answer", "answerText" : {"_value" : "
While we have no specific plans to do so, we are committed to expanding and transforming mental health services in England through the NHS Long Term Plan, so that more people, including those experiencing side effects from taking gabapentin, can get the mental health help and support that they need.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T15:56:56.633Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Gabapentin"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will take steps to ensure that people experiencing acute or chronic side effects from taking gabapentin do not have to wait for a (a) referral and (b) assessment by mental health services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23891"}
, {"_about" : "http://data.parliament.uk/resources/1714081", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714081/answer", "answerText" : {"_value" : "
Guidance from England\u2019s Chief Medical Officer for healthcare professionals is clear, an alcohol-free childhood is the healthiest and best option. The Department promotes this through online platforms such as the NHS.UK website, and the Talk to FRANK online resource. Local authorities promote these guidelines as part of their public health duties.<\/p>
The Department for Education\u2019s statutory guidance, Relationships education, relationships and sex education and health education, became mandatory in September 2020. Through this, education on drugs, alcohol, and tobacco became compulsory at state-funded primary and secondary schools, teaching children and young people how to manage influences and pressures, and keep themselves healthy and safe.<\/p>
To deter individuals selling alcohol to a person aged under 18 years old, the maximum fine for the offence of persistently selling alcohol to children was increased from £10,000 to £20,000, under s 147A(8) of the 2003 Licensing Act.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"}
}
, "answeringMemberConstituency" : {"_value" : "South Northamptonshire"}
, "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T12:20:25.667Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Alcoholic Drinks: Children and Young Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to help tackle under-age alcohol use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23892"}
, {"_about" : "http://data.parliament.uk/resources/1714094", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714094/answer", "answerText" : {"_value" : "
NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.<\/p>
In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England\u2019s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.<\/p>
To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times.\u202fThe centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.<\/p>
In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23908"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T08:52:14.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases: Surgery"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4571", "label" : {"_value" : "Biography information for Gill Furniss"}
}
, "tablingMemberConstituency" : {"_value" : "Sheffield, Brightside and Hillsborough"}
, "tablingMemberPrinted" : [{"_value" : "Gill Furniss"}
], "uin" : "23907"}
, {"_about" : "http://data.parliament.uk/resources/1714095", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714095/answer", "answerText" : {"_value" : "
NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.<\/p>
In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England\u2019s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.<\/p>
To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times.\u202fThe centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.<\/p>
In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23907"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T08:52:14.607Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases: Women"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4571", "label" : {"_value" : "Biography information for Gill Furniss"}
}
, "tablingMemberConstituency" : {"_value" : "Sheffield, Brightside and Hillsborough"}
, "tablingMemberPrinted" : [{"_value" : "Gill Furniss"}
], "uin" : "23908"}
, {"_about" : "http://data.parliament.uk/resources/1714123", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714123/answer", "answerText" : {"_value" : "
The Joint Committee on Vaccination and Immunisation has recommended that those who are eligible for the shingles vaccine should change, to allow individuals to be protected at an earlier age, particularly those that have a weakened immune system. Based on the evidence, they recognised that there may be more clinical benefit from starting shingles vaccinations at a lower age, with modelling indicating that a greater number of cases of shingles would be prevented with vaccination at 60 years old for immunocompetent individuals, and 50 years old for immunosuppressed individuals. The committee advised that the programme should be implemented in stages, starting with those that are over 50 years old with a weakened immune system and those turning 65 and 70 years old, then eventually moving down to those turning 60 years old. This is a similar pattern to the roll out of the shingles vaccine from 2013. This is why the vaccine offer has been expanded to all those turning 65 and 70 years old and all those over 50 years old with a weakened immune system, from 1 September 2023. The programme began on 1 September 2023 and will run until 31 August 2028, offering the vaccine to people as they turn 65 and 70 years old, until the offer has been made to all those aged 65 to 70 years old. It will then expand to offering the vaccine to all those that are turning 60 and 65 years old, from 1 September 2028.<\/p>
The shingles vaccine is available through general practice (GP) surgeries in primary care, and GPs are required to identify and put in place a call or recall arrangement to offer the shingles vaccination to eligible patients. All eligible patients are contacted by their GP surgery to invite them for vaccination. The GP will then follow up with letters or with calls and text messages, to encourage eligible people that have not come forward to take up the offer.<\/p>
<\/p>
There is a wide range of public facing information to help increase uptake of the shingles vaccine, and to publicise the programme in GP surgeries and online, including display bunting, leaflets, and posters. GPs are also adding messages regarding shingles to their practice websites, prescription counterfoils, and social media banners. Public facing information regarding the shingles vaccination programme includes translations into over 20 different languages including braille, audio, large print, and British Sign Language. Information for healthcare professionals, including GP toolkits for improving uptake of shingles vaccination, has also been produced and published by local immunisation commissioning teams.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T12:52:34.487Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Shingles: Warrington"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase uptake of the shingles vaccine by people aged over 65 in Warrington.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4791", "label" : {"_value" : "Biography information for Andy Carter"}
}
, "tablingMemberConstituency" : {"_value" : "Warrington South"}
, "tablingMemberPrinted" : [{"_value" : "Andy Carter"}
], "uin" : "23963"}
, {"_about" : "http://data.parliament.uk/resources/1714139", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1714139/answer", "answerText" : {"_value" : "
The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff.<\/p>
There are a number of key national programmes aimed at supporting regions, integrated care boards (ICBs), and providers with recruitment challenges, and growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment, encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.<\/p>
The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICS), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, thereby reducing NHS staff leaver rates.<\/p>
<\/p>
Support for organisations and ICS can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues to support the retention agenda in each of the seven regions.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T11:26:40.5Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Professions: Labour Turnover"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she has had with Integrated Care Boards on recruitment and retention of health workers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol South"}
, "tablingMemberPrinted" : [{"_value" : "Karin Smyth"}
], "uin" : "23888"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2024-04-26T14%3A08%3A26.057Z&answeringDeptId=17&max-questionFirstAnswered.=2024-05-02T11%3A47%3A11.07Z", "page" : 0, "startIndex" : 1, "totalResults" : 84001, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}